Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sho Fukui, Satoshi Kawaai, Haruki Sawada & Mitsumasa Kishimoto. (2023) Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Expert Review of Clinical Immunology 0:0, pages 1-13.
Read now
Read now
Jürgen Braun, Uta Kiltz & Xenofon Baraliakos. (2022) Management of Axial Spondyloarthritis – Insights into Upadacitinib. Drug Design, Development and Therapy 16, pages 3609-3620.
Read now
Read now
Eleftherios Pelechas, Paraskevi V Voulgari & Alexandros A. Drosos. (2021) Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opinion on Drug Discovery 16:3, pages 227-234.
Read now
Read now
Articles from other publishers (41)
Margaux J. Heuschkel, Charlotte Bach, Laura Meiss-Heydmann, Emma Gerges, Emanuele Felli, Fabio Giannone, Patrick Pessaux, Catherine Schuster, Julie Lucifora, Thomas F. Baumert & Eloi R. Verrier. (2023) JAK1 promotes HDV replication and is a potential target for antiviral therapy. Journal of Hepatology.
Crossref
Crossref
Jeremy Martinez, Cyriac Manjaly, Priya Manjaly, Sophia Ly, Guohai Zhou, John Barbieri & Arash Mostaghimi. (2023) Janus Kinase Inhibitors and Adverse Events of Acne. JAMA Dermatology.
Crossref
Crossref
Yuanxin Li, Bo Li, Gang Wang, Juanjuan Su, Yilin Qiao, Chao Ma, Fan Wang, Jian Zhu, Jingjing Li, Hongjie Zhang, Kai Liu & Huji Xu. (2023) Engineered protein and Jakinib nanoplatform with extraordinary rheumatoid arthritis treatment. Nano Research 16:8, pages 11197-11205.
Crossref
Crossref
Maria Luisa Faquetti, Enriqueta Vallejo-Yagüe, René Cordtz, Lene Dreyer & Andrea M. Burden. (2023) JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register. PLOS ONE 18:7, pages e0288757.
Crossref
Crossref
Menglin Zhu, Qian Ding, Zhongxiao Lin, Rong Fu, Fuyuan Zhang, Zhaoyi Li, Mei Zhang & Yizhun Zhu. (2023) New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect. Biomolecules 13:5, pages 766.
Crossref
Crossref
Haizhen A. Zhong & Suliman Almahmoud. (2023) Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors. International Journal of Molecular Sciences 24:7, pages 6023.
Crossref
Crossref
Qian Ding, Wei Hu, Ran Wang, Qinyan Yang, Menglin Zhu, Meng Li, Jianghong Cai, Peter Rose, Jianchun Mao & Yi Zhun Zhu. (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Viraj Panchal, Bhavya H Vyas, Barath Prashanth Sivasubramanian, Kanan Panchal & Harshank Patel. (2023) A Meta-Analysis Evaluating the Effectiveness and Safety of Upadacitinib in Treating Rheumatoid Arthritis in Patients With Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs. Cureus.
Crossref
Crossref
Erumalla Venkata Nagaraju. (2023) In-silico Prediction of Maximum Binding Affinity of Disease-Modifying Antirheumatic Drugs with Homo sapiens Acrosomal Protein SP-10. International Journal of Pharmaceutical Research And Allied Sciences 12:1, pages 59-65.
Crossref
Crossref
Jan Portegys, Anke Heidemeier, Andreas Rosenwald, Michael Gernert, Matthias Fröhlich, Sebastian Hueper, Patrick Pascal Strunz, Leo Rasche & Marc Schmalzing. (2023) Erdheim-Chester disease with Rosai-Dorfman-like lesions: treatment with methotrexate, anakinra and upadacitinib. RMD Open 9:1, pages e002852.
Crossref
Crossref
Minjie Zhang, Peng Cui, Kai Zhang, Zhen Shi, Xu Cheng, Xiang Ji, Hao Song, Bowen Ke & Yong Qin. (2023) Asymmetric hydrogenation of all-carbon tetrasubstituted α-acylpyrazole-β-alkyl cycloalkenes. Organic Chemistry Frontiers.
Crossref
Crossref
Griffin R. Lee, Dylan E. Lee & Vivian Y. Shi. 2023. Atopic Dermatitis : Inside Out Or Outside in. Atopic Dermatitis : Inside Out Or Outside in
237
251
.
Ruchi P. Agashe, Scott M. Lippman & Razelle Kurzrock. (2022) JAK: Not Just Another Kinase. Molecular Cancer Therapeutics 21:12, pages 1757-1764.
Crossref
Crossref
Magesh Sampath, Sembian Ruso Jayaraman, Vishnuvardhan Reddy Eda, Rajendar Potham, Rajeev Rehani Budhdev, Saikat Sen, Rakeshwar Bandichhor & Srinivas Oruganti. (2022)
Enantioselective Synthesis of the Chiral Pyrrolidine Fragment of Upadacitinib
via
Chiral Auxiliary Directed Diastereoselective 1,3-Dipolar Cycloaddition
. Organic Process Research & Development 26:6, pages 1794-1802.
Crossref
Crossref
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, Ahmed H. Abdelazeem & Ahmed M. Gouda. (2022) A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics 14:5, pages 1001.
Crossref
Crossref
Hanan S. Anbar, Naglaa G. Shehab, Nadia M.M. El-Rouby, Marium A. Ansari, Haseena Chenoth, Maham Majeed, Komal Naeem, Fatima Hersi & Hany A. Omar. (2022) Upadacitinib protects against cisplatin-induced renal and hepatic dysfunction without impairing its anticancer activity. European Journal of Pharmaceutical Sciences 172, pages 106149.
Crossref
Crossref
Suchitra Nishal, Vikas Jhawat, Parmita Phaugat & Rohit Dutt. (2022) Rheumatoid Arthritis and JAK-STAT Inhibitors: Prospects of Topical Delivery. Current Drug Therapy 17:2, pages 86-95.
Crossref
Crossref
Michael J. Rozema, Lakshmi Bhagavatula, Alan Christesen, Travis B. Dunn, Andrew Ickes, Brian J. Kotecki, James C. Marek, Eric Moschetta, Westin H. Morrill, Mathew Mulhern, Michael Rasmussen, Troy Reynolds & Su Yu. (2021) Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib. Organic Process Research & Development 26:3, pages 949-962.
Crossref
Crossref
E. Yu. Loginova & T. V. Korotaeva. (2022) Janus kinase inhibitors in the treatment of psoriatic arthritis. Modern Rheumatology Journal 16:1, pages 7-13.
Crossref
Crossref
V. N. Amirjanova, A. E. Karateev, E. Y. Pogozheva, A. A. Baranov, V. I. Mazurov, R. R. Samigullina, O. N. Anoshenkova, N. A. Lapkina, T. Yu. Grineva, E. L. Nasonov & A. M. Lila. (2021) The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”). Rheumatology Science and Practice 59:5, pages 571-577.
Crossref
Crossref
Johanna Karlsson Sundbaum, Eva Baecklund, Niclas Eriksson, Hugo Kohnke, Matilda Wallenberg, Marco Cavalli, Claes Wadelius, Mia Wadelius & Pär Hallberg. (2021) Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate. Pharmacogenomics 22:15, pages 973-982.
Crossref
Crossref
Shuang Liu, Hongxing Ma, Huaxi Zhang, Chengjie Deng & Ping Xin. (2021) Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clinical Immunology 230, pages 108793.
Crossref
Crossref
Fabiola Atzeni, Javier Rodríguez-Carrio, Călin D. Popa, Michael T. Nurmohamed, Gabriella Szűcs & Zoltán Szekanecz. (2021) Cardiovascular effects of approved drugs for rheumatoid arthritis. Nature Reviews Rheumatology 17:5, pages 270-290.
Crossref
Crossref
G. Pongratz. (2021) Schmerz bei rheumatischen ErkrankungenPain in rheumatic diseases. Zeitschrift für Rheumatologie 80:3, pages 214-225.
Crossref
Crossref
Rita A. Moura & João Eurico Fonseca. (2021) JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis. Frontiers in Medicine 7.
Crossref
Crossref
Carlos Alves, Ana Penedones, Diogo Mendes & Francisco Batel-Marques. (2020) Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses. BMJ Open 10:12, pages e041420.
Crossref
Crossref
E. L. Nasonov & A. M. Lila. (2020) The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. Rheumatology Science and Practice 58:5, pages 532-543.
Crossref
Crossref
Bergithe E. Oftedal & Anette S. B. Wolff. (2020) New era of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology 92:5.
Crossref
Crossref
Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Yijie Zhou, Ahmed A Othman, Aileen L Pangan, Susumu Kitamura, Sebastian Meerwein & Yoshiya Tanaka. (2020) Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology 59:11, pages 3303-3313.
Crossref
Crossref
Ronald van Vollenhoven, Tsutomu Takeuchi, Aileen L. Pangan, Alan Friedman, Mohamed‐Eslam F. Mohamed, Su Chen, Maureen Rischmueller, Ricardo Blanco, Ricardo M. Xavier & Vibeke Strand. (2020) Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial. Arthritis & Rheumatology 72:10, pages 1607-1620.
Crossref
Crossref
Sanjiv Singh & Shantanu Singh. (2020) JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis. International Immunopharmacology 86, pages 106731.
Crossref
Crossref
E. L. Nasonov & A. M. Lila. (2020) BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES. Rheumatology Science and Practice 58:3, pages 304-316.
Crossref
Crossref
Urspeter Masche. (2020) Upadacitinib. pharma-kritik 41:12.
Crossref
Crossref
Blaž Burja, Tonja Mertelj & Mojca Frank-Bertoncelj. (2020) Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors. Frontiers in Medicine 7.
Crossref
Crossref
Miao Chen & Sheng-Ming Dai. (2020) A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chinese Medical Journal 133:8, pages 959-967.
Crossref
Crossref
Tariq Al Shehri, Kimberly Gilmour, Florian Gothe, Sam Loughlin, Shahnaz Bibi, Andrew D. Rowan, Angela Grainger, Thivytra Mohanadas, Andrew J. Cant, Mary A. Slatter, Sophie Hambleton, Desa Lilic & Timothy R. Leahy. (2019) Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib. Journal of Clinical Immunology 39:8, pages 776-785.
Crossref
Crossref
Daniele Mannina & Nicolaus Kröger. (2019) Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects. Drugs 79:14, pages 1499-1509.
Crossref
Crossref
Wenhui Xie, Yanrong Huang, Shiyu Xiao, Xiaoying Sun, Yong Fan & Zhuoli Zhang. (2019) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Annals of the Rheumatic Diseases 78:8, pages 1048-1054.
Crossref
Crossref
Köhler, Günther, Kaudewitz & Lorenz. (2019) Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. Journal of Clinical Medicine 8:7, pages 938.
Crossref
Crossref
E. L. Nasonov & A. M. Lila. (2019) Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Rheumatology Science and Practice 57:1, pages 8-16.
Crossref
Crossref
Steven H. Spergel, Michael E. Mertzman, James Kempson, Junqing Guo, Sylwia Stachura, Lauren Haque, Jonathan S. Lippy, Rosemary F. Zhang, Michael Galella, Sidney Pitt, Guoxiang Shen, Aberra Fura, Kathleen Gillooly, Kim W. McIntyre, Vicky Tang, John Tokarski, John S. Sack, Javed Khan, Percy H. Carter, Joel C. Barrish, Steven G. Nadler, Luisa M. Salter-Cid, Gary L. Schieven, Stephen T. Wrobleski & William J. Pitts. (2019) Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. ACS Medicinal Chemistry Letters 10:3, pages 306-311.
Crossref
Crossref